| Followers | 1130 |
| Posts | 32802 |
| Boards Moderated | 3 |
| Alias Born | 01/11/2016 |
Monday, April 13, 2026 11:40:39 PM
PSTV going to rock the house soon. This is going to moon soon.
Recent PSTV News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:46:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:33:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:13:11 PM
- Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout • GlobeNewswire Inc. • 05/15/2026 08:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 04:21:08 PM
- Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases • GlobeNewswire Inc. • 05/08/2026 11:30:00 AM
- Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ • GlobeNewswire Inc. • 04/23/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:04 PM
- Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/22/2026 08:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 12:30:16 PM
- Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/21/2026 11:30:00 AM
- Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 12:01:12 PM
- Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline • GlobeNewswire Inc. • 04/09/2026 11:30:00 AM
- Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment • IH Market News • 04/08/2026 02:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2026 11:30:07 AM
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas • GlobeNewswire Inc. • 04/08/2026 11:30:00 AM
- Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:12 PM
- Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:03 AM
